The board of Dishman Carbogen Amcis Limited (NSE:DCAL) met on 12 August 2026 and approved the issuance of up to 7,500 Senior, Secured, Rated, Listed, Transferable, Redeemable, Taxable Non-Convertible Debentures of Rs 1,00,000 each, aggregating up to Rs 75 crores, on a private placement basis.
Key Highlights
- The board approved up to 7,500 NCDs of face value Rs 1,00,000 each, aggregating up to Rs 75 crores, to be placed on a private placement basis with eligible investors.
- The NCDs carry a coupon rate of 10.00% per annum, with interest payable quarterly and principal repayment as a bullet payment at maturity after 18 months from allotment.
- The tentative allotment date is 17 August 2026, with a maturity date of 17 February 2028, subject to completion of applicable requirements.
- The instruments will be listed on the Wholesale Debt Market segment of BSE Limited, and will be secured at 1.1x security cover through a mortgage over land in Ahmedabad district provided by Dishman Infrastructure Limited.
About the Company
Dishman Carbogen Amcis Limited (NSE:DCAL), headquartered in Ahmedabad, Gujarat, is a contract development and manufacturing organisation operating in the global pharmaceutical and life sciences sector. The company provides active pharmaceutical ingredient synthesis, CRAMS services, and specialty chemical manufacturing through facilities in India, Europe, and other geographies, serving regulated markets across the world.
Announcement in Detail
At a board meeting commencing at 10:30 a.m. and concluding at 11:10 a.m. on 12 August 2026, the directors of Dishman Carbogen Amcis Limited approved the issuance of up to 7,500 NCDs at a face value of Rs 1,00,000 each, aggregating up to Rs 75 crores in one or more tranches as mutually agreed. The debentures are described as senior, secured, rated, listed, transferable, redeemable, and taxable, and will be offered on a private placement basis to all eligible investors.
The NCDs are to be secured at a 1.1x security cover. Security arrangements include a first ranking and exclusive mortgage over approximately 1,71,476 square metres of non-agriculture land at Mouje Gangad/Kalyangadh, Taluka Bavla, District Ahmedabad, owned by Dishman Infrastructure Limited (DIL). An unconditional and irrevocable corporate guarantee from DIL, a demand promissory note, and a letter of continuity form additional layers of the security structure disclosed in the filing.
Impact on Investors
Investors will note that this is a debt instrument issued on a private placement basis and does not involve dilution of equity shareholding. The filing shows the NCDs carry a fixed coupon of 10.00% per annum with quarterly interest payments, offering a defined income schedule to debenture holders. The bullet repayment structure means principal is returned only at the end of the 18-month tenure, which investors in the debt instruments should factor into their liquidity assessment.
Shareholders will observe that the security cover of 1.1x is backed by land belonging to a related entity, Dishman Infrastructure Limited, along with a corporate guarantee from that entity. The disclosed terms indicate that actual allotment and maturity dates may shift depending on the completion of regulatory and procedural requirements, as explicitly noted in the filing.
Sector / Market Context
India's contract research and manufacturing services sector has seen sustained demand from global pharmaceutical companies seeking to diversify supply chains away from single-country dependence. According to industry bodies such as FICCI and the Pharmaceuticals Export Promotion Council, India's pharmaceutical exports exceeded USD 27 billion in FY25, underlining the scale of the domestic CRAMS and API manufacturing base within which Dishman Carbogen Amcis operates. Private placement of NCDs remains a common fund-raising route for mid-sized listed companies seeking capital without equity dilution, in line with SEBI's debt market development objectives.